Quantum BioPharma Ltd. (QNTM)
QNTM Stock Price Chart
Explore Quantum BioPharma Ltd. interactive price chart. Choose custom timeframes to analyze QNTM price movements and trends.
QNTM Company Profile
Discover essential business fundamentals and corporate details for Quantum BioPharma Ltd. (QNTM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
8 Jun 2018
Employees
17.00
Website
https://www.quantumbiopharma.comCEO
Zeeshan Saeed
Description
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
QNTM Financial Timeline
Browse a chronological timeline of Quantum BioPharma Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.41.
Earnings released on 7 May 2026
EPS came in at -$3.06 falling short of the estimated -$0.49 by -524.01%.
Earnings released on 26 Mar 2026
EPS came in at -$0.71 surpassing the estimated -$1.02 by +30.49%.
Earnings released on 7 Nov 2025
EPS came in at -$1.25 falling short of the estimated -$0.20 by -525.00%.
Earnings released on 6 Aug 2025
EPS came in at -$3.23 falling short of the estimated -$0.17 by -1.80k%.
Earnings released on 14 May 2025
EPS came in at -$1.41 falling short of the estimated -$0.37 by -281.08%, while revenue for the quarter reached $2.17m , meeting expectations.
Earnings released on 28 Mar 2025
EPS came in at -$2.89 falling short of the estimated -$0.80 by -261.25%.
Stock split effective on 15 Aug 2024
Shares were split 1 : 65 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Aug 2024
EPS came in at -$5.20 falling short of the estimated -$3.90 by -33.33%.
Earnings released on 14 May 2024
EPS came in at -$3.25 matching the estimated -$3.25.
Earnings released on 28 Mar 2024
EPS came in at -$0.04 surpassing the estimated -$9.31 by +99.57%.
Earnings released on 15 Nov 2023
EPS came in at -$1.95 surpassing the estimated -$9.09 by +78.53%.
Earnings released on 20 Jul 2023
EPS came in at -$9.31 .
Earnings released on 12 May 2023
EPS came in at -$16.61 .
Earnings released on 11 Nov 2022
Earnings released on 15 Nov 2021
EPS came in at -$9.57 .
Earnings released on 12 Aug 2021
EPS came in at -$22.88 .
QNTM Stock Performance
Access detailed QNTM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
